Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Paul Knight
KEY
Paul Knight
Wall Street Analyst
★★☆☆☆
#2298
on 13Foresight · ranked by our own returns
44%
Success Rate
-0.6%
Average Return
16 of 36 calls profitable · -14.4% vs benchmark
📈 Across the calls we could measure, roughly 44% of Paul Knight's ratings turned a profit when each position was held for 1 year — averaging -0.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

23 Buy 12 Hold 0 Sell
Paul's Stock Coverage 46 ratings · 2026-06-20
Company Date Position Consensus Price Target 1-Yr Return
CSTL
Castle Biosciences
May 29, 2026 BUY Strong Buy
+96.2% avg upside
9 analysts
$35.00
65.65% Upside
·
RPID
Rapid Micro Biosystems
May 29, 2026 BUY Strong Buy
+411.7% avg upside
6 analysts
$5.00
192.39% Upside
-16.4%
CYRX
CryoPort
May 20, 2026 BUY Strong Buy
-4.3% avg upside
15 analysts
$17.00
13.20% Upside
·
TECH
Bio-Techne
May 07, 2026 HOLD Strong Buy
+38.3% avg upside
21 analysts
+10.3%
XGN
Exagen
Mar 11, 2026 BUY Strong Buy
+159.4% avg upside
10 analysts
$10.00
120.21% Upside
+17.0%
STVN
Stevanato Group
Mar 05, 2026 BUY Strong Buy
+53.7% avg upside
13 analysts
$32.00
82.37% Upside
-84.7%
TKNO
Alpha Teknova
Feb 27, 2026 HOLD Strong Buy
+173.6% avg upside
7 analysts
+100.8%
LAB
Standard BioTools
Feb 25, 2026 HOLD Strong Buy
+645.1% avg upside
8 analysts
-16.2%
RGEN
Repligen
Feb 25, 2026 BUY Strong Buy
+28.4% avg upside
25 analysts
$220.00
66.73% Upside
-7.4%
LFCR
Lifecore Biomedical
Dec 29, 2025 HOLD Strong Buy
+73.8% avg upside
9 analysts
-33.1%
DHR
Danaher
Dec 18, 2025 BUY Strong Buy
+21.9% avg upside
45 analysts
$310.00
74.97% Upside
-20.5%
TMO
Thermo Fisher
Dec 08, 2025 BUY Strong Buy
+26.8% avg upside
38 analysts
$750.00
61.37% Upside
-18.5%
WST
West Pharmaceutical Services
Oct 24, 2025 BUY Strong Buy
+6.5% avg upside
17 analysts
$350.00
6.75% Upside
+11.0%
DE:SRT3
Sartorius
Oct 07, 2025 BUY Buy
+27.9% avg upside
17 analysts
$320.00
47.52% Upside
·
BLFS
BioLife Solutions
Oct 03, 2025 BUY Strong Buy
+12.8% avg upside
17 analysts
$33.00
26.64% Upside
-9.9%
RVTY
Revvity
Sep 16, 2025 BUY Buy
+5.2% avg upside
23 analysts
$125.00
25.02% Upside
+14.9%
ATR
AptarGroup
Sep 10, 2025 BUY Buy
+14.4% avg upside
14 analysts
$220.00
82.77% Upside
-12.5%
CH:YPSN
Ypsomed Holding AG
Sep 04, 2025 BUY Strong Buy
+44.0% avg upside
2 analysts
$525.00
49.84% Upside
·
A
Agilent
Aug 28, 2025 HOLD Strong Buy
+3.8% avg upside
32 analysts
+0.1%
WAT
Waters
Aug 18, 2025 BUY Strong Buy
+3.6% avg upside
30 analysts
$460.00
29.49% Upside
+23.4%
AVTR
Avantor
Jun 03, 2025 BUY Buy
+49.6% avg upside
26 analysts
$30.00
213.13% Upside
-31.0%
HBIO
Harvard Bioscience
Apr 09, 2025 HOLD Strong Buy
+161.2% avg upside
3 analysts
$30.00
411.09% Upside
+16.7%
DE:GXI
Gerresheimer
Mar 31, 2025 HOLD Buy
+143.3% avg upside
14 analysts
·
MLAB
Mesa Laboratories
Feb 05, 2025 HOLD Buy
+48.3% avg upside
5 analysts
-34.0%
CH:LONN
Lonza Group Ltd
Jan 30, 2025 BUY Strong Buy
+26.0% avg upside
19 analysts
$635.00
28.09% Upside
·
MRVI
Maravai Lifesciences Holdings
May 09, 2024 HOLD Strong Buy
+175.0% avg upside
17 analysts
-79.9%
AZTA
Azenta
Nov 14, 2023 HOLD Buy
+101.3% avg upside
13 analysts
-21.7%
TBIO
Telesis Bio
Aug 11, 2023 HOLD Buy
+7199900.0% avg upside
7 analysts
-4.9%
CRL
Charles River Labs
May 05, 2022 BUY Strong Buy
+11.9% avg upside
34 analysts
$300.00
62.08% Upside
-22.9%
IQV
IQVIA Holdings
Apr 28, 2022 BUY Strong Buy
+34.5% avg upside
38 analysts
$250.00
48.99% Upside
-14.2%
IMDX
Insight Molecular Diagnostics
Mar 14, 2022 HOLD Buy
-1.2% avg upside
10 analysts
·
IDXG
Interpace Diagnostics Group
Apr 15, 2020 BUY Strong Buy
+617.5% avg upside
9 analysts
·
NEO
NeoGenomics
Feb 27, 2020 HOLD Strong Buy
+37.2% avg upside
17 analysts
$30.00
169.54% Upside
+85.3%
TTOO
T2 Biosystems
Nov 26, 2019 HOLD Buy
+1421150.0% avg upside
10 analysts
$2.00
399899.97% Upside
·
CSBR
Champions Oncology
Jul 24, 2019 HOLD Strong Buy
+34.6% avg upside
6 analysts
+31.3%
VCYT
Veracyte
Nov 29, 2018 HOLD Strong Buy
-20.7% avg upside
17 analysts
+136.0%
ILMN
Illumina
Oct 23, 2017 HOLD Buy
-10.1% avg upside
30 analysts
+48.3%
BRKR
Bruker
Mar 27, 2017 HOLD Buy
-7.0% avg upside
22 analysts
+30.1%
CRDF
Cardiff Oncology
Mar 11, 2016 HOLD Strong Buy
+732.8% avg upside
18 analysts
-66.7%
CDNA
CareDx
Feb 10, 2016 BUY Buy
+25.1% avg upside
16 analysts
-50.7%
IEX
IDEX
Jul 24, 2014 HOLD Buy
-10.6% avg upside
22 analysts
$85.00
62.24% Downside
-4.5%
PLUG
Plug Power
May 05, 2014 BUY Buy
+231.7% avg upside
45 analysts
-40.4%
NEOG
Neogen
Dec 19, 2013 HOLD Buy
+148.1% avg upside
6 analysts
$46.00
394.12% Upside
+9.8%
QGEN
Qiagen
Aug 15, 2013 HOLD Buy
+14.1% avg upside
23 analysts
$24.00
35.10% Downside
+14.4%
SFES
Safeguard Scientifics
Aug 15, 2013 HOLD Buy
+3786.2% avg upside
2 analysts
$18.00
3581.77% Upside
·
MTD
Mettler-Toledo
Aug 15, 2013 HOLD Buy
+2.7% avg upside
18 analysts
$255.00
77.67% Downside
+18.3%
🔒 41 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Paul Knight — Frequently Asked Questions
How accurate are Paul Knight's stock ratings?
Based on the calls 13Foresight could measure, about 44% of Paul's ratings were profitable over a one-year hold, with an average return of -0.6% per rating, or -14.4% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Paul ranked on 13Foresight?
Paul Knight is currently ranked #2298 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Paul cover?
Paul most recently has ratings on CSTL, RPID, CYRX, TECH, XGN, STVN, TKNO, LAB, RGEN, LFCR, DHR, TMO and 34 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.